Skip to main content

Gano Kyle's Form 4 filing

Neurocrine Biosciences Inc (NBIX) · filed Feb 14, 2025

Accession no.
0000914475-25-000063
Filed
Feb 14, 2025
Trade date
Feb 12-13, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market sales total $298.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gano KyleCIK 0001567160Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 13, 2025Common StockMOption exerciseAcquired+2,566$0.00$0140,224Direct
Feb 13, 2025Common StockSSaleDisposed−1,352$116.84−$157,967.68138,872Direct
Feb 13, 2025Common StockMOption exerciseAcquired+2,241$0.00$0141,113Direct
Feb 13, 2025Common StockSSaleDisposed−1,206$116.86−$140,933.16139,907Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 12, 2025Common StockAGrant or awardAcquired+104,736$0.00$0104,736Direct
Feb 12, 2025Common StockAGrant or awardAcquired+19,628$0.00$019,628Direct
Feb 13, 2025Common StockMOption exerciseDisposed−2,566$0.00$05,132Direct
Feb 13, 2025Common StockMOption exerciseDisposed−2,241$0.00$06,725Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)